Business Description
![Perspective Therapeutics Inc Perspective Therapeutics Inc logo](https://static.gurufocus.com/logos/0C00000FMD.png?14)
Perspective Therapeutics Inc
NAICS : 339112
SIC : 5047
ISIN : US46489V1044
Description
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 62.77 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 10.81 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -43.7 | |||||
3-Year EPS without NRI Growth Rate | -40.9 | |||||
3-Year FCF Growth Rate | -34.8 | |||||
3-Year Book Growth Rate | 47.5 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 77.01 | |||||
9-Day RSI | 68.7 | |||||
14-Day RSI | 61.62 | |||||
6-1 Month Momentum % | 52.06 | |||||
12-1 Month Momentum % | 58.47 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.98 | |||||
Quick Ratio | 12.98 | |||||
Cash Ratio | 12.46 | |||||
Days Inventory | 193.31 | |||||
Days Payable | 747.81 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -59.9 | |||||
Shareholder Yield % | -6.11 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 232.4 | |||||
Operating Margin % | 2348.31 | |||||
Net Margin % | 3192.4 | |||||
FCF Margin % | 1272.4 | |||||
ROE % | -46.33 | |||||
ROA % | -39.77 | |||||
ROIC % | -56.72 | |||||
ROC (Joel Greenblatt) % | -456.6 | |||||
ROCE % | -30.27 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.49 | |||||
Price-to-Tangible-Book | 5.15 | |||||
EV-to-EBIT | -17.97 | |||||
EV-to-EBITDA | -18.47 | |||||
EV-to-Revenue | -404.6 | |||||
EV-to-Forward-Revenue | 1063.05 | |||||
EV-to-FCF | -31.8 | |||||
Price-to-Projected-FCF | 7.7 | |||||
Price-to-Net-Current-Asset-Value | 5.76 | |||||
Price-to-Net-Cash | 6.09 | |||||
Earnings Yield (Greenblatt) % | -5.56 | |||||
FCF Yield % | -2.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:CATX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Perspective Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | -1.83 | ||
EPS (TTM) ($) | -1.9 | ||
Beta | 2.12 | ||
Volatility % | 142.43 | ||
14-Day RSI | 61.62 | ||
14-Day ATR ($) | 0.92427 | ||
20-Day SMA ($) | 11.794 | ||
12-1 Month Momentum % | 58.47 | ||
52-Week Range ($) | 2.05 - 19.05 | ||
Shares Outstanding (Mil) | 67.41 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Perspective Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Perspective Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Perspective Therapeutics Inc Frequently Asked Questions
What is Perspective Therapeutics Inc(CATX)'s stock price today?
The current price of CATX is $13.70. The 52 week high of CATX is $19.05 and 52 week low is $2.05.
When is next earnings date of Perspective Therapeutics Inc(CATX)?
The next earnings date of Perspective Therapeutics Inc(CATX) is 2024-08-09 Est..
Does Perspective Therapeutics Inc(CATX) pay dividends? If so, how much?
Perspective Therapeutics Inc(CATX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |